Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 3/1/2014 |
| Start Date: | May 2012 |
| End Date: | May 2014 |
| Contact: | Iris McNulty, RN |
| Email: | imcnulty@partners.org |
| Phone: | 617 726 2612 |
It has been hypothesized that one of the benefits of bosentan relates to pulmonary vascular
remodeling. The investigators believe that this study will help document the nature of
beneficial changes that occur in patients with Pulmonary Arterial Hypertension (PAH) in
response to bosentan therapy. In turn, demonstrating that changes in pulmonary vascular
structure and function accompany clinical improvement.
remodeling. The investigators believe that this study will help document the nature of
beneficial changes that occur in patients with Pulmonary Arterial Hypertension (PAH) in
response to bosentan therapy. In turn, demonstrating that changes in pulmonary vascular
structure and function accompany clinical improvement.
Subjects will have Optical coherence tomography (OCT) and Intravascular Ultrasound (IVUS)
imaging during the right heart catheterization that diagnoses them as having PAH. Subjects
will start their bosentan and will be followed by monthly clinic visits for 4 months. At 4
months they will have repeat OCT and IVUS imaging.
imaging during the right heart catheterization that diagnoses them as having PAH. Subjects
will start their bosentan and will be followed by monthly clinic visits for 4 months. At 4
months they will have repeat OCT and IVUS imaging.
Inclusion Criteria:
1. WHO GROUP 1
2. AGE 18-75
3. Baseline 6-min walk distance (6MWD) between 200 and 450 m
4. Diagnosed with pulmonary artery hypertension during right heart catheterization (Mean
Pulmonary Artery Pressure > 25mmHg)
General Exclusion Criteria
1. Pregnant or nursing
2. Acute or chronic illness other than those associated with PAH (collagen vascular
disease, human immunodeficiency virus, or anorexigen use)
3. Previously received any investigational medications, prostanoids, or
phosphodiesterase inhibitors
4. eGFR < 60
5. Angina
6. Syncope
7. Failing right ventricle
8. Hemoptysis
We found this trial at
1
site
Click here to add this to my saved trials
